These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 20473925)

  • 41. Multimodal Treatment Eliminates Cancer Stem Cells and Leads to Long-Term Survival in Primary Human Pancreatic Cancer Tissue Xenografts.
    Hermann PC; Trabulo SM; Sainz B; Balic A; Garcia E; Hahn SA; Vandana M; Sahoo SK; Tunici P; Bakker A; Hidalgo M; Heeschen C
    PLoS One; 2013; 8(6):e66371. PubMed ID: 23825539
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A Polymeric Nanogel-Based Treatment Regimen for Enhanced Efficacy and Sequential Administration of Synergistic Drug Combination in Pancreatic Cancer.
    Soni KS; Thomas D; Caffrey T; Mehla K; Lei F; O'Connell KA; Sagar S; Lele SM; Hollingsworth MA; Radhakrishnan P; Bronich TK
    J Pharmacol Exp Ther; 2019 Sep; 370(3):894-901. PubMed ID: 30683666
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer.
    Venkatasubbarao K; Peterson L; Zhao S; Hill P; Cao L; Zhou Q; Nawrocki ST; Freeman JW
    Mol Cancer; 2013 Sep; 12(1):104. PubMed ID: 24025152
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Interleukin-13 receptor-targeted cancer therapy in an immunodeficient animal model of human head and neck cancer.
    Kawakami K; Kawakami M; Joshi BH; Puri RK
    Cancer Res; 2001 Aug; 61(16):6194-200. PubMed ID: 11507072
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Genexol inhibits primary tumour growth and metastases in gemcitabine-resistant pancreatic ductal adenocarcinoma.
    Shea JE; Nam KH; Rapoport N; Scaife CL
    HPB (Oxford); 2011 Mar; 13(3):153-7. PubMed ID: 21309930
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Rosiglitazone and Gemcitabine in combination reduces immune suppression and modulates T cell populations in pancreatic cancer.
    Bunt SK; Mohr AM; Bailey JM; Grandgenett PM; Hollingsworth MA
    Cancer Immunol Immunother; 2013 Feb; 62(2):225-36. PubMed ID: 22864396
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer.
    Bianco C; Giovannetti E; Ciardiello F; Mey V; Nannizzi S; Tortora G; Troiani T; Pasqualetti F; Eckhardt G; de Liguoro M; Ricciardi S; Del Tacca M; Raben D; Cionini L; Danesi R
    Clin Cancer Res; 2006 Dec; 12(23):7099-107. PubMed ID: 17145834
    [TBL] [Abstract][Full Text] [Related]  

  • 48.
    Tadros S; Shukla SK; King RJ; Gunda V; Vernucci E; Abrego J; Chaika NV; Yu F; Lazenby AJ; Berim L; Grem J; Sasson AR; Singh PK
    Cancer Res; 2017 Oct; 77(20):5503-5517. PubMed ID: 28811332
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Superior therapeutic efficacy of nab-paclitaxel over cremophor-based paclitaxel in locally advanced and metastatic models of human pancreatic cancer.
    Rajeshkumar NV; Yabuuchi S; Pai SG; Tong Z; Hou S; Bateman S; Pierce DW; Heise C; Von Hoff DD; Maitra A; Hidalgo M
    Br J Cancer; 2016 Aug; 115(4):442-53. PubMed ID: 27441498
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mesothelin blockage by Amatuximab suppresses cell invasiveness, enhances gemcitabine sensitivity and regulates cancer cell stemness in mesothelin-positive pancreatic cancer cells.
    Matsuzawa F; Kamachi H; Mizukami T; Einama T; Kawamata F; Fujii Y; Fukai M; Kobayashi N; Hatanaka Y; Taketomi A
    BMC Cancer; 2021 Feb; 21(1):200. PubMed ID: 33637083
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evaluation of poly-mechanistic antiangiogenic combinations to enhance cytotoxic therapy response in pancreatic cancer.
    Awasthi N; Zhang C; Ruan W; Schwarz MA; Schwarz RE
    PLoS One; 2012; 7(6):e38477. PubMed ID: 22723862
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Difluoromethylornithine Combined with a Polyamine Transport Inhibitor Is Effective against Gemcitabine Resistant Pancreatic Cancer.
    Gitto SB; Pandey V; Oyer JL; Copik AJ; Hogan FC; Phanstiel O; Altomare DA
    Mol Pharm; 2018 Feb; 15(2):369-376. PubMed ID: 29299930
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Lurbinectedin induces depletion of tumor-associated macrophages, an essential component of its in vivo synergism with gemcitabine, in pancreatic adenocarcinoma mouse models.
    Céspedes MV; Guillén MJ; López-Casas PP; Sarno F; Gallardo A; Álamo P; Cuevas C; Hidalgo M; Galmarini CM; Allavena P; Avilés P; Mangues R
    Dis Model Mech; 2016 Dec; 9(12):1461-1471. PubMed ID: 27780828
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pegylated arginine deiminase synergistically increases the cytotoxicity of gemcitabine in human pancreatic cancer.
    Daylami R; Muilenburg DJ; Virudachalam S; Bold RJ
    J Exp Clin Cancer Res; 2014 Dec; 33(1):102. PubMed ID: 25499121
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Mechanisms of metformin's anti‑tumor activity against gemcitabine‑resistant pancreatic adenocarcinoma.
    Suzuki K; Takeuchi O; Suzuki Y; Kitagawa Y
    Int J Oncol; 2019 Feb; 54(2):764-772. PubMed ID: 30570108
    [TBL] [Abstract][Full Text] [Related]  

  • 56. CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer.
    Neesse A; Frese KK; Bapiro TE; Nakagawa T; Sternlicht MD; Seeley TW; Pilarsky C; Jodrell DI; Spong SM; Tuveson DA
    Proc Natl Acad Sci U S A; 2013 Jul; 110(30):12325-30. PubMed ID: 23836645
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Potentiation of gemcitabine by Turmeric Force in pancreatic cancer cell lines.
    Ramachandran C; Resek AP; Escalon E; Aviram A; Melnick SJ
    Oncol Rep; 2010 Jun; 23(6):1529-35. PubMed ID: 20428806
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Combined effect of dehydroxymethylepoxyquinomicin and gemcitabine in a mouse model of liver metastasis of pancreatic cancer.
    Suzuki K; Aiura K; Matsuda S; Itano O; Takeuchi O; Umezawa K; Kitagawa Y
    Clin Exp Metastasis; 2013 Apr; 30(4):381-92. PubMed ID: 23111540
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Combination chemotherapy with gemcitabine and biotherapy with opioid growth factor (OGF) enhances the growth inhibition of pancreatic adenocarcinoma.
    Zagon IS; Jaglowski JR; Verderame MF; Smith JP; Leure-Dupree AE; McLaughlin PJ
    Cancer Chemother Pharmacol; 2005 Nov; 56(5):510-20. PubMed ID: 15947928
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Up-regulation of HER2 by gemcitabine enhances the antitumor effect of combined gemcitabine and trastuzumab emtansine treatment on pancreatic ductal adenocarcinoma cells.
    Kan S; Koido S; Okamoto M; Hayashi K; Ito M; Kamata Y; Komita H; Nagasaki E; Homma S
    BMC Cancer; 2015 Oct; 15():726. PubMed ID: 26475267
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.